These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10194550)

  • 1. Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice.
    Hua J; Pero RW; Kane R
    Anticancer Drugs; 1999 Jan; 10(1):79-88. PubMed ID: 10194550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antitumor activity of declopramide (3-chloroprocainamide) and N-acetyl-declopramide.
    Hua J; Sheng Y; Bryngelsson C; Kane R; Pero RW
    Anticancer Res; 1999; 19(1A):285-90. PubMed ID: 10226556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide.
    Pero RW; Olsson A; Simanaitis M; Amiri A; Andersen I
    Pharmacol Toxicol; 1997 May; 80(5):231-9. PubMed ID: 9181602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity, antitumor and chemosensitizing effects of 3-chloroprocainamide.
    Hua J; Pero RW
    Acta Oncol; 1997; 36(8):811-6. PubMed ID: 9482687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action for N-substituted benzamide-induced apoptosis.
    Olsson AR; Lindgren H; Pero RW; Leanderson T
    Br J Cancer; 2002 Mar; 86(6):971-8. PubMed ID: 11953831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
    Hamik A; Peroutka SJ
    Cancer Chemother Pharmacol; 1989; 24(5):307-10. PubMed ID: 2527092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
    Hirokawa Y; Morie T; Yamazaki H; Yoshida N; Kato S
    Bioorg Med Chem Lett; 1998 Mar; 8(6):619-24. PubMed ID: 9871571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
    Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
    Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-substituted benzamides inhibit NFkappaB activation and induce apoptosis by separate mechanisms.
    Liberg D; Lazarevic B; Pero RW; Leanderson T
    Br J Cancer; 1999 Nov; 81(6):981-8. PubMed ID: 10576654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers.
    Rotmensch HH; Mould GP; Sutton JA; Kilminster S; Moller C; Pero RW
    J Clin Pharmacol; 1997 Mar; 37(3):222-8. PubMed ID: 9089424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of DNA-damaging, clastogenic, and promoting activities of metoclopramide and procainamide in rats.
    Mereto E; Robbiano L; Ghia M; Allavena A; Martelli A; Brambilla G
    Toxicol Appl Pharmacol; 1995 Apr; 131(2):192-7. PubMed ID: 7716761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.
    Herrstedt J; Hyttel J; Pedersen J
    Cancer Chemother Pharmacol; 1993; 33(1):53-6. PubMed ID: 8269589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between metoclopramide and morphine: enhanced antinociception and motor dysfunction in rats.
    Kamerman PR; Becker N; Fick LG
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):106-12. PubMed ID: 17201744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
    Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
    J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent response of central dopaminergic systems to metoclopramide in mice.
    Bhosale KB; Balsara JJ; Gaonkar RK; Bhosale BB; Gupta SK
    Indian J Exp Biol; 1997 Jun; 35(6):618-22. PubMed ID: 9357166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
    Stemp G; Ashmeade T; Branch CL; Hadley MS; Hunter AJ; Johnson CN; Nash DJ; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Avenell KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Routledge C; Wood M
    J Med Chem; 2000 May; 43(9):1878-85. PubMed ID: 10794704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.